Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
CSNK2A1 and PTEN	casein kinase 2, alpha 1 polypeptide	phosphatase and tensin homolog	Mitotic Prometaphase Signal transduction by L1 Axon guidance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling L1CAM interactions Signaling by Wnt Cell Cycle, Mitotic M Phase WNT mediated activation of DVL TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Condensation of Prometaphase Chromosomes	Signaling by the B Cell Receptor (BCR) Downstream TCR signaling Metabolism of lipids and lipoproteins Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Synthesis of PIPs at the plasma membrane Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation Synthesis of IP3 and IP4 in the cytosol PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Phospholipid metabolism PI Metabolism Innate Immune System Signaling by PDGF DAP12 interactions Signalling by NGF GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Negative regulation of the PI3K/AKT network Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Inositol phosphate metabolism PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR TCR signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	(5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One Resveratrol 1,8-Di-Hydroxy-4-Nitro-Anthraquinone Benzamidine 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone Phosphoaminophosphonic Acid-Adenylate Ester Tetrabromo-2-Benzotriazole DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole 1,2,5,8-tetrahydroxyanthracene-9,10-dione Ellagic Acid
CSNK2A2 and PTEN	casein kinase 2, alpha prime polypeptide	phosphatase and tensin homolog	Mitotic Prometaphase Signal transduction by L1 Axon guidance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling L1CAM interactions Signaling by Wnt Cell Cycle, Mitotic M Phase WNT mediated activation of DVL TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Condensation of Prometaphase Chromosomes	Signaling by the B Cell Receptor (BCR) Downstream TCR signaling Metabolism of lipids and lipoproteins Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Synthesis of PIPs at the plasma membrane Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation Synthesis of IP3 and IP4 in the cytosol PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Phospholipid metabolism PI Metabolism Innate Immune System Signaling by PDGF DAP12 interactions Signalling by NGF GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Negative regulation of the PI3K/AKT network Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Inositol phosphate metabolism PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR TCR signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System
CSNK2A2 and TCF7L2	casein kinase 2, alpha prime polypeptide	transcription factor 7-like 2 (T-cell specific, HMG-box)	Mitotic Prometaphase Signal transduction by L1 Axon guidance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling L1CAM interactions Signaling by Wnt Cell Cycle, Mitotic M Phase WNT mediated activation of DVL TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Condensation of Prometaphase Chromosomes	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated S37 mutants of beta-catenin aren't phosphorylated Peptide hormone metabolism Degradation of beta-catenin by the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Incretin synthesis, secretion, and inactivation truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
CSNK2B and CTNNB1	casein kinase 2, beta polypeptide	catenin (cadherin-associated protein), beta 1, 88kDa	Mitotic Prometaphase Signal transduction by L1 Axon guidance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling L1CAM interactions Signaling by Wnt Cell Cycle, Mitotic M Phase WNT mediated activation of DVL TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Condensation of Prometaphase Chromosomes	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer		Urea
CTBP1 and TCF7L2	C-terminal binding protein 1	transcription factor 7-like 2 (T-cell specific, HMG-box)	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated Degradation of beta-catenin by the destruction complex S37 mutants of beta-catenin aren't phosphorylated S33 mutants of beta-catenin aren't phosphorylated RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling XAV939 inhibits tankyrase, stabilizing AXIN truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated S37 mutants of beta-catenin aren't phosphorylated Peptide hormone metabolism Degradation of beta-catenin by the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Incretin synthesis, secretion, and inactivation truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
CTBP1 and CTBP2	C-terminal binding protein 1	C-terminal binding protein 2	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated Degradation of beta-catenin by the destruction complex S37 mutants of beta-catenin aren't phosphorylated S33 mutants of beta-catenin aren't phosphorylated RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling XAV939 inhibits tankyrase, stabilizing AXIN truncations of AMER1 destabilize the destruction complex misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes deletions in the AMER1 gene destabilize the destruction complex TCF dependent signaling in response to WNT AMER1 mutants destabilize the destruction complex deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex
CTBP2 and TGIF1	C-terminal binding protein 2	TGFB-induced factor homeobox 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Loss of Function of TGFBR1 in Cancer Generic Transcription Pathway Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer SMAD4 MH2 Domain Mutants in Cancer
CTBP2 and NRIP1	C-terminal binding protein 2	nuclear receptor interacting protein 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex
CTBP2 and PSMF1	C-terminal binding protein 2	proteasome (prosome, macropain) inhibitor subunit 1 (PI31)	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex	Hedgehog 'off' state misspliced GSK3beta mutants stabilize beta-catenin Hh ligand biogenesis disease T41 mutants of beta-catenin aren't phosphorylated Downstream signaling events of B Cell Receptor (BCR) Degradation of beta-catenin by the destruction complex Stabilization of p53 S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Regulation of mRNA stability by proteins that bind AU-rich elements misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling DNA Replication Pre-Initiation S45 mutants of beta-catenin aren't phosphorylated APC/C:Cdc20 mediated degradation of mitotic proteins Regulation of APC/C activators between G1/S and early anaphase SCF(Skp2)-mediated degradation of p27/p21 deletions in the AMER1 gene destabilize the destruction complex Autodegradation of the E3 ubiquitin ligase COP1 AMER1 mutants destabilize the destruction complex Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint PCP/CE pathway Adaptive Immune System CDK-mediated phosphorylation and removal of Cdc6 Hedgehog ligand biogenesis APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Separation of Sister Chromatids HIV Infection Ubiquitin-dependent degradation of Cyclin D APC truncation mutants have impaired AXIN binding Assembly of the pre-replicative complex Autodegradation of Cdh1 by Cdh1:APC/C p53-Dependent G1 DNA Damage Response S37 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN p53-Independent DNA Damage Response p53-Independent G1/S DNA damage checkpoint G1/S DNA Damage Checkpoints Vpu mediated degradation of CD4 Synthesis of DNA M/G1 Transition Ubiquitin-dependent degradation of Cyclin D1 TCF dependent signaling in response to WNT SCF-beta-TrCP mediated degradation of Emi1 degradation of AXIN Signaling by Hedgehog Regulation of mitotic cell cycle Degradation of GLI1 by the proteasome degradation of DVL Cell Cycle Checkpoints Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Regulation of Apoptosis Degradation of GLI2 by the proteasome Signaling by the B Cell Receptor (BCR) Vif-mediated degradation of APOBEC3G Ubiquitin Mediated Degradation of Phosphorylated Cdc25A p53-Dependent G1/S DNA damage checkpoint truncated APC mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP Signaling by Wnt Cyclin E associated events during G1/S transition APC/C:Cdc20 mediated degradation of Securin AUF1 (hnRNP D0) destabilizes mRNA CDK-mediated phosphorylation and removal of Cdc6 RNF mutants show enhanced WNT signaling and proliferation G1/S Transition truncations of AMER1 destabilize the destruction complex Processing-defective Hh variants abrogate ligand secretion Host Interactions of HIV factors phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex Regulation of activated PAK-2p34 by proteasome mediated degradation AXIN missense mutants destabilize the destruction complex S Phase APC/C-mediated degradation of cell cycle proteins Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Mitotic Metaphase and Anaphase Regulation of ornithine decarboxylase (ODC) Antigen processing: Ubiquitination & Proteasome degradation Orc1 removal from chromatin Mitotic Anaphase M Phase APC truncation mutants are not K63 polyubiquitinated Metabolism of amino acids and derivatives Hedgehog 'on' state Programmed Cell Death Class I MHC mediated antigen processing & presentation Regulation of DNA replication Cell Cycle, Mitotic beta-catenin independent WNT signaling Orc1 removal from chromatin Activation of NF-kappaB in B cells Asymmetric localization of PCP proteins deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Cross-presentation of soluble exogenous antigens (endosomes) Antigen processing-Cross presentation CDT1 association with the CDC6:ORC:origin complex ER-Phagosome pathway
CTBP2 and STUB1	C-terminal binding protein 2	STIP1 homology and U-box containing protein 1, E3 ubiquitin protein ligase	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Antigen processing: Ubiquitination & Proteasome degradation Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by ERBB2 Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer Class I MHC mediated antigen processing & presentation SMAD4 MH2 Domain Mutants in Cancer Adaptive Immune System
CTBP2 and ZNF512B	C-terminal binding protein 2	zinc finger protein 512B	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex
CTBP2 and PPP1R15A	C-terminal binding protein 2	protein phosphatase 1, regulatory subunit 15A	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex	Loss of Function of TGFBR2 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer SMAD4 MH2 Domain Mutants in Cancer
CTBP2 and DVL2	C-terminal binding protein 2	dishevelled segment polarity protein 2	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex	misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Signaling by Wnt negative regulation of TCF-dependent signaling by DVL-interacting proteins beta-catenin independent WNT signaling disassembly of the destruction complex and recruitment of AXIN to the membrane WNT mediated activation of DVL Signaling by Hippo TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation Asymmetric localization of PCP proteins WNT5A-dependent internalization of FZD4 XAV939 inhibits tankyrase, stabilizing AXIN degradation of DVL Signaling by WNT in cancer PCP/CE pathway
CTBP2 and PLCB1	C-terminal binding protein 2	phospholipase C, beta 1 (phosphoinositide-specific)	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex	G alpha (q) signalling events Signaling by GPCR Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Integration of energy metabolism G beta:gamma signalling through PLC beta Signaling by Wnt Synthesis of IP3 and IP4 in the cytosol Gastrin-CREB signalling pathway via PKC and MAPK Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell PLC beta mediated events G-protein beta:gamma signalling Opioid Signalling Regulation of insulin secretion G-protein mediated events Activation of Kainate Receptors upon glutamate binding Inositol phosphate metabolism beta-catenin independent WNT signaling Presynaptic function of Kainate receptors G alpha (q) signalling events GPCR downstream signaling Acetylcholine regulates insulin secretion Ca2+ pathway Free fatty acids regulate insulin secretion Transmission across Chemical Synapses
CTBP2 and HIST3H3	C-terminal binding protein 2	histone cluster 3, H3	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex	DNA Damage/Telomere Stress Induced Senescence Meiotic recombination Chromosome Maintenance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Mitotic Prophase formation of the beta-catenin:TCF transactivating complex Cellular Senescence Meiotic synapsis Signaling by Wnt Cell Cycle, Mitotic M Phase Telomere Maintenance Packaging Of Telomere Ends TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Condensation of Prophase Chromosomes
CTBP2 and HIC1	C-terminal binding protein 2	hypermethylated in cancer 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex
CTBP2 and EP300	C-terminal binding protein 2	E1A binding protein p300	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by Wnt APC truncation mutants are not K63 polyubiquitinated repression of WNT target genes S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer truncations of AMER1 destabilize the destruction complex	Signaling by NOTCH1 HD Domain Mutants in Cancer Metabolism of lipids and lipoproteins Signaling by Wnt NOTCH2 intracellular domain regulates transcription Regulation of gene expression by Hypoxia-inducible Factor Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Signaling by NOTCH2 Pre-NOTCH Transcription and Translation RNF mutants show enhanced WNT signaling and proliferation Signaling by NOTCH1 in Cancer Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex Factors involved in megakaryocyte development and platelet production Chromatin modifying enzymes LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Signaling by NOTCH1 PEST Domain Mutants in Cancer Mitotic G2-G2/M phases Constitutive Signaling by NOTCH1 PEST Domain Mutants PPARA activates gene expression Cellular response to hypoxia Regulation of Hypoxia-inducible Factor (HIF) by oxygen Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Attenuation phase G2/M Transition HATs acetylate histones RORA activates circadian gene expression HSF1-dependent transactivation TRAF3-dependent IRF activation pathway Signaling by NOTCH1 Transcriptional regulation of white adipocyte differentiation XAV939 inhibits tankyrase, stabilizing AXIN Pre-NOTCH Expression and Processing Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer Innate Immune System Fatty acid, triacylglycerol, and ketone body metabolism Cytosolic sensors of pathogen-associated DNA Cellular response to heat stress REV-ERBA represses gene expression Cell Cycle, Mitotic RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways NOTCH1 Intracellular Domain Regulates Transcription TCF dependent signaling in response to WNT TRAF6 mediated IRF7 activation Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) Signaling by WNT in cancer BMAL1:CLOCK,NPAS2 activates circadian gene expression Polo-like kinase mediated events
CTNNB1 and BOC	catenin (cadherin-associated protein), beta 1, 88kDa	BOC cell adhesion associated, oncogene regulated	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Hedgehog 'on' state Signaling by Hedgehog Ligand-receptor interactions	Urea
CTNNB1 and KAT2A	catenin (cadherin-associated protein), beta 1, 88kDa	K(lysine) acetyltransferase 2A	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by NOTCH1 HD Domain Mutants in Cancer RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Clearance HATs acetylate histones Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway Pre-NOTCH Transcription and Translation Signaling by NOTCH1 Pre-NOTCH Expression and Processing Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer Chromatin organization RNA Polymerase I Transcription Signaling by NOTCH Notch-HLH transcription pathway NOTCH1 Intracellular Domain Regulates Transcription Chromatin modifying enzymes Signaling by NOTCH1 PEST Domain Mutants in Cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants	Urea
CTNNB1 and HIF1A	catenin (cadherin-associated protein), beta 1, 88kDa	hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by NOTCH1 HD Domain Mutants in Cancer Cellular response to hypoxia Regulation of Hypoxia-inducible Factor (HIF) by oxygen Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha Signaling by NOTCH Regulation of gene expression by Hypoxia-inducible Factor Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant NOTCH1 Intracellular Domain Regulates Transcription Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha Signaling by NOTCH1 Signaling by NOTCH1 PEST Domain Mutants in Cancer Signaling by NOTCH1 in Cancer FBXW7 Mutants and NOTCH1 in Cancer	Urea

Search Results for: Cancer